All In Biotech

Drug Trial Radar · NCT06277128

A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Clinical Trial to Investigate the Efficacy and Safety of WS016 in the Patients With Hyperkalemia

Last checked: Nov 19, 2026Latest source record: Feb 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

140

Planned (sponsor's estimate)

Start

Sep 11, 2023

Primary completion

Apr 18, 2024

Study completion Aug 4, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy of different doses of WS016(3g, 6g and 12g) orally administered three times a day for 48 hours (acute treatment phase) vs placebo in the treatment of hyperkalemia, and to evaluate the efficacy of WS016(3g, 6g and 12g) orally administered once daily for 12 days ( maintenance treatment phase) vs placebo in maintaining normokalemia in participants have returned to normokalemia after the acute treatment phase.

Conditions

  • Hyperkalemia

Interventions

  • WS016 3gDrug

    Acute treatment phase: WS016, oral, 3g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 3g, once daily for 12 days.

  • WS016 6gDrug

    Acute treatment phase: WS016, oral, 6g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 6g, once daily for 12 days.

  • WS016 12gDrug

    Acute treatment phase: WS016, oral, 12g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 12g, once daily for 12 days.

  • Matching PlaceboDrug

    Acute treatment phase: Matching Placebo, oral, three times a day for 48 hours; Maintenance treatment phase: Matching Placebo, oral, once daily for 12 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Exponential rate of change in serum potassium(S-K) levels during the acute treatment phaseTime frame: Through the initial 48-hour acute treatment phase (from baseline to hour 48)
  2. Exponential rate of change in S-K levels during the maintenance treatment phaseTime frame: Through 12 days of maintenance treatment phase (from Day 3 to Day 15)

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Shougang Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Zhongshan Hospital, Xiamen University

    Xiamen, Fujian, China · Recruiting

  • The Affiliated Hospital of Hebei University

    Baoding, Hebei, China · Recruiting

  • Hebei Traditional Chinese Medicine Hospital

    Shijiazhuang, Hebei, China · Recruiting

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • The First Hospital of Qiqihar

    Qiqihar, Heilongjiang, China · Recruiting

  • The First People's Hospital of Nanyang City

    Nanyang, Henan, China · Recruiting

  • Puyang Oilfield General Hospital

    Puyang, Henan, China · Recruiting

  • Shiyan Taihe Hospital

    Shiyan, Hubei, China · Recruiting

  • Wuhan No.4 Hospital

    Wuhan, Hubei, China · Recruiting

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China · Recruiting

  • Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China · Recruiting

  • Sir Run Run Hospital, Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China · Recruiting

  • Shenyang Central Hospital, affiliated to Shenyang Medical College

    Shenyang, Liaoning, China · Recruiting

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China · Recruiting

  • The First People's Hospital of Tancheng County

    Linyi, Shandong, China · Recruiting

  • Qilu Hospital of Shandong University (Qingdao)

    Qingdao, Shandong, China · Recruiting

  • Minhang District Central Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai First People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai No.5 Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Tongji Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • The Second Affiliated Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China · Recruiting

  • Tianjin People's Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.